

P.E.I. Pharmacare Bulletin

Issue (2019-8)

Sept 19, 2019

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (Effective Date: October 1, 2019)

Product (Generic Name)	Product (Brand Name)	Strength	Dosage Form	DIN	MFR
Palbociclib	<u>lbrance</u>	75 mg 100 mg 125 mg	Capsule Capsule Capsule	02453150 02453169 02453177	PFI
Criteria	<p>In combination with an aromatase inhibitor for the treatment of estrogen receptor positive, HER2 negative advanced breast cancer in postmenopausal women who:</p> <ul style="list-style-type: none"> • have not received prior therapy for metastatic disease and • are not resistant to (neo)adjuvant non-steroidal aromatase inhibitor (NSAI) therapy and • do not have active or uncontrolled metastases to the central nervous system. <p>Renewal Criteria:</p> <ul style="list-style-type: none"> • Written confirmation that the patient has responded to treatment and there is no evidence of disease progression. <p>Clinical Notes:</p> <ul style="list-style-type: none"> • Patients must have a good performance status. • Resistance is defined as disease progression occurring during or within 12 months following NSAI therapy • Treatment should be discontinued upon disease progression or unacceptable toxicity. <p>Claim Notes: Initial approval period: 1 year Renewal approval period: 1 year</p>				
Program Eligibility	High Cost Drug Program, Catastrophic Drug Program				